RESEARCH TRIANGLE PARK – Drug giant GSK will expand its sales reach for its Shingrix shingles vaccine in China under terms of a $3 billion deal announced Monday.

Another deal could follow with GSK’ syncytial virus (RSV) deal.

The deal is with Chongqing Zhifei Biological Products, which FiercePharma describes as a “vaccine powerhouse.”

FiercePharma has the details.